Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $70
Scotiabank analyst George Farmer maintains $Legend Biotech(LEGN.US)$ with a buy rating, and adjusts the target price from $65 to $70.According to TipRanks data, the analyst has a success rate of 60.2%
Express News | Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday.Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $70 to $94
On Jul 18, major Wall Street analysts update their ratings for $Legend Biotech(LEGN.US)$, with price targets ranging from $70 to $94.Barclays analyst Gena Wang maintains with a buy rating, and
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating on Legend Biotech: Strong Carvykti Sales and High Market Potential Signal Upside
Express News | Legend Biotech Corp : Scotiabank Raises Target Price to $70 From $65
Express News | HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Genscript Biotech Unit Logs $186 Million in Net Trade Sales From Carvykti in April-June
Genscript Biotech's (HKG:1548) US-listed unit Legend Biotech logged $186.0 million in net trade sales of its Carvykti drug in the three months through June 30, according to a Wednesday filing with
Legend biotech's (LEGN.US) CAR-T product sales in the second quarter reached $0.186 billion.
Legend biotech (LEGN.US) announced that according to the cooperation and license agreement signed with Johnson & Johnson on December 21, 2017, Legend Biotech announced on July 17, 2024, that the net sales of CAR-T therapy CARVYKTI were approximately 0.186 billion US dollars for the quarter ended June 30, 2024.
Legend Biotech's Preliminary CARVYKTI Sales Report
Express News | Legend Biotech Corp -Announced Carvykti Generated About $186 Mln in Net Trade Sales During the Quarter Ended June 30, 2024
J&J Beats in Q2 as Pharma Segment Outperforms
Hong Kong stock market news | Genscript Bio (01548) fell more than 4%, with a total market value of over 25 billion Hong Kong dollars. Reports suggest that Legend Biotech may have received a takeover offer.
Genscript Bio (01548) fell more than 4%, and as of press time, it fell by 3.67% to HKD 12.08, with a turnover of 0.168 billion HKD, and a total market value exceeding 25 billion HKD.
The Latest Analyst Ratings For Legend Biotech
In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish.The table below summarizes their
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating
Legend Biotech (LEGN) has an average rating of outperform and price targets ranging from $60 to $95, according to analysts polled by Capital IQ.Price: 53.44, Change: -0.93, Percent Change: -1.71
Legend Biotech Is Maintained at Buy by TD Cowen
Legend Biotech Is Maintained at Buy by TD
Legend Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 23.14% TD Cowen $71 → $67 Maintains Buy 07/03/2024 65.41% BMO Capital $90 → $90 Maintains
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?